Despite their advantages, combination products present new technological and organizational challenges. They require new product development strategies compared to standalone products, drugs, and devices.
Wicked problems – chronic health issues such as diabetes, obesity, and endocrine disorders – are projected to affect close to one billion people worldwide by 2045. By planning ahead and investing in digital healthcare solutions for connected drug delivery, companies such as Novo Nordisk are aiming to meet rising demands for the provision of healthcare as they occur.
In this commentary article, we present Axel Becker's insights on the latest techniques governing API particle properties and the processes that dictate the success of drug reception and tablet compression.
This month, the discussion group debated the advantages and disadvantages of different types of inhalers. One key area of interest was current-day challenges with aerosol delivery, which could be addressed through smart inhalers and other innovative new devices.
Beyond the blood–brain barrier, the pulmonary power of nebulisers, and RNA science in the post-COVID era
Edited by Tom Cohen |
11 February 2022
RNA Formulation & Delivery
Search by Keyword
Filter by Subject Area
Filter by Content Type
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.